Key result
Lutein pretreatment prevented doxorubicin-induced vascular toxicity by preserving vascular functions, reducing inflammation and apoptosis, and modulating autophagic processes.
Why the study?
Doxorubicin impairs heart and arterial function, but whether lutein can prevent doxorubicin-associated vascular toxicity was unknown.
Does lutein pretreatment prevent doxorubicin-induced vascular toxicity in male Wistar rats?
Does lutein pretreatment prevent doxorubicin-induced vascular toxicity in male Wistar rats?
Lutein pretreatment preserves vascular function and mitigates doxorubicin-induced vascular toxicity in a rat model through antioxidant, anti-inflammatory, and anti-apoptotic mechanisms.
Lutein may attenuate DOX vascular toxicity in rats; leaves open any clinical translation or human relevance.
Doxorubicin (DOX) treatment has been well-reported to hamper heart and arterial function, limiting its clinical application. Meanwhile lutein (LUT) has shown promising therapeutic prospects against many diseases, but no report has shown whether LUT can prevent DOX-associated vascular toxicity. This study deciphers the mechanism of Lutein's preventive effect against DOX-induced vascular toxicity using rat model. Twenty-four rats were grouped into the control (10 mL/kg distilled water with 1% dimethyl sulfoxide (DMSO), the DOX (15 mg/kg DOX in 1% DMSO), Lutein (LUT: 40 mg/kg) and LUT+DOX groups and used for this study. Male experimental rats were pretreated with Lutein and distilled water in 1% DMSO for 28 days to establish a preventive experimental model while, DOX were given to DOX and LUT+DOX groups for 3 days starting from day 25. Vascular function, oxido-inflammatory, aortic apoptotic, autophagy and histopathology were assessed. lutein pretreatment mechanistically showed upregulation of nitric oxide (NO) bioavailability, reducing endothelin-1 (ET-1), increased glutathione (GSH), superoxide dismutase (SOD), glutathione S-transferase (GST) as well as catalase while reducing inflammation (tumor necrosis factor-α and interleukin-6) and apoptosis (caspase 3) were significantly reduced through modulation of autophagic processes (Beclin-1/mammalian target of rapamycin (mTOR)). Also, histopathological changes were markedly alleviated. This study suggests that lutein-mediated vaso-preventive effect against DOX-induced vascular toxicity by preserving the vascular functions.
No takes yet. Share an insight, caveat, or question.
Asiwe et al. (2025) studied Doxorubicin-induced vascular toxicity (n=24). Lutein vs. Doxorubicin alone and vehicle control was evaluated on Vascular function, oxido-inflammatory, aortic apoptotic, autophagy and histopathology. Lutein pretreatment prevented doxorubicin-induced vascular toxicity by preserving vascular functions, reducing inflammation and apoptosis, and modulating autophagic processes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: